With 3.16 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.13 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $7.78 whereas the lowest price it dropped to was $6.8801. The 52-week range on NTRB shows that it touched its highest point at $11.78 and its lowest point at $3.72 during that stretch. It currently has a 1-year price target of $15.00. Beta for the stock currently stands at 1.30.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NTRB was down-trending over the past week, with a drop of -2.98%, but this was down by -12.56% over a month. Three-month performance surged to 26.23% while six-month performance rose 7.50%. The stock gained 52.23% in the past year, while it has gained 44.27% so far this year. A look at the trailing 12-month EPS for NTRB yields -0.90 with Next year EPS estimates of 1.57. For the next quarter, that number is -0.17. This implies an EPS growth rate of 43.43% for this year and 380.36% for next year.
Float and Shares Shorts:
At present, 11.13 million NTRB shares are outstanding with a float of 5.13 million shares on hand for trading. On 2025-07-15, short shares totaled 0.11 million, which was 97.0 higher than short shares on 1749772800. In addition to Mr. Serguei Melnik as the firm’s Founder, President, Company Secretary & Executive Chairman of the Board, Mr. Gareth Sheridan serves as its Founder, CEO & Director.
Institutional Ownership:
Through their ownership of 0.031 of NTRB’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-04-30, NTRB reported revenue of $667432.0 and operating income of -$1413497.0. The EBITDA in the recently reported quarter was -$1325509.0 and diluted EPS was $nan.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With NTRB analysts setting a high price target of 15.0 and a low target of 15.0, the average target price over the next 12 months is 15.0. Based on these targets, NTRB could surge 109.21% to reach the target high and rise by 109.21% to reach the target low. Reaching the average price target will result in a growth of 109.21% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.23 being high and -$0.23 being low. For NTRB, this leads to a yearly average estimate of -$0.23. Based on analyst estimates, the high estimate for the next quarter is -$0.19 and the low estimate is -$0.19. The average estimate for the next quarter is thus -$0.19.
